中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 7
Jul.  2024
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(7): 1307-1311

Research advances in the treatment of cervical cancer with liver metastasis

DOI: 10.12449/JCH240704
  • 1.

    Department of Gynecology，The Obstetrics & Gynecology Hospital of Tongji University，Shanghai 201204，China

  • 2.

    Department of Radiotherapy，Tongren Hospital，Shanghai Jiaotong University School of Medicine，Shanghai 200000，China

Research funding:

General Project of National Natural Science Foundation of China (82272778)

More Information
  • Corresponding author: ZHU Haiyan， zhuhaiyandoc@sina.com （ORCID： 0000-0002-1030-4601）
  • Received Date: 2024-04-10
  • Accepted Date: 2024-05-11
  • Published Date: 2024-07-25
    Abstract
  • Though liver metastasis of cervical cancer has a relatively low incidence rate， it is often accompanied by metastasis in other sites and thus has a poor prognosis. For the patients with liver metastasis of cervical cancer， it is necessary to formulate individualized treatment regimens based on various factors such as general status， lesion distribution， initial treatment modality， and life expectancy， so as to prolong the overall survival of patients and improve their quality of life. With reference to related studies in China and globally， this article reviews the clinical features， treatment， and prognosis of cervical cancer with liver metastasis.

     

    • FullText(HTML)
  • loading
    • References(41)
  • [1]
    SUNG H, FERLAY J, SIEGEL RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71( 3): 209- 249. DOI: 10.3322/caac.21660.
    [2]
    ZHANG Y, GUO Y, ZHOU X, et al. Prognosis for different patterns of distant metastases in patients with uterine cervical cancer: A population-based analysis[J]. J Cancer, 2020, 11( 6): 1532- 1541. DOI: 10.7150/jca.37390.
    [3]
    LI PP, SU YH, ZHANG MZ. Hepatic metastases after cervical cancer surgery: clinical analysis of 13 cases[J]. Chin J Obstetr Gynecol, 2020, 55( 4): 266- 272. DOI: 10.3760/cma.j.cn112141-20200114-00033.

    李盼盼, 苏玥辉, 张梦真. 子宫颈癌术后肝转移13例临床分析[J]. 中华妇产科杂志, 2020, 55( 4): 266- 272. DOI: 10.3760/cma.j.cn112141-20200114-00033.
    [4]
    LIU H, YE XS, LI D, et al. Incidence, clinical risk and prognostic factors for liver metastasis in patients with cervical cancer: A population-based retrospective study[J]. BMC Cancer, 2021, 21( 1): 421. DOI: 10.1186/s12885-021-08127-6.
    [5]
    KIM GE, LEE SW, SUH CO, et al. Hepatic metastases from carcinoma of the uterine cervix[J]. Gynecol Oncol, 1998, 70( 1): 56- 60. DOI: 10.1006/gyno.1998.5037.
    [6]
    GARDNER AB, CHARO LM, MANN AK, et al. Ovarian, uterine, and cervical cancer patients with distant metastases at diagnosis: Most common locations and outcomes[J]. Clin Exp Metastasis, 2020, 37( 1): 107- 113. DOI: 10.1007/s10585-019-10007-0.
    [7]
    DING X, WANG QY, MA LL, et al. Analysis of risk factors of postoperative liver metastasis in patients with early cervical cancer[J]. Chin J Woman Child Health Res, 2023, 34( 6): 95- 101. DOI: 10.3969/j.issn.1673-5293.2023.06.014.

    丁鑫, 王乾印, 马亮亮, 等. 早期子宫颈癌患者术后发生肝转移的危险因素分析[J]. 中国妇幼健康研究, 2023, 34( 6): 95- 101. DOI: 10.3969/j.issn.1673-5293.2023.06.014.
    [8]
    PARK KJ. Cervical adenocarcinoma: Integration of HPV status, pattern of invasion, morphology and molecular markers into classification[J]. Histopathology, 2020, 76( 1): 112- 127. DOI: 10.1111/his.13995.
    [9]
    DOLL KM. Investigating Black-White disparities in gynecologic oncology: Theories, conceptual models, and applications[J]. Gynecol Oncol, 2018, 149( 1): 78- 83. DOI: 10.1016/j.ygyno.2017.10.002.
    [10]
    YU LL, SABATINO SA, WHITE MC. Rural-urban and racial/ethnic disparities in invasive cervical cancer incidence in the United States, 2010-2014[J]. Prev Chronic Dis, 2019, 16: E70. DOI: 10.5888/pcd16.180447.
    [11]
    SCATCHARD K, FORREST JL, FLUBACHER M, et al. Chemotherapy for metastatic and recurrent cervical cancer[J]. Cochrane Database Syst Rev, 2012, 10( 10): CD006469. DOI: 10.1002/14651858.CD006469.pub2.
    [12]
    MOORE DH, BLESSING JA, MCQUELLON RP, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: A gynecologic oncology group study[J]. J Clin Oncol, 2004, 22( 15): 3113- 3119. DOI: 10.1200/JCO.2004.04.170.
    [13]
    LONG HJ 3, BUNDY BN, GRENDYS EC Jr, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: A Gynecologic Oncology Group Study[J]. J Clin Oncol, 2005, 23( 21): 4626- 4633. DOI: 10.1200/JCO.2005.10.021.
    [14]
    ABU-RUSTUM NR, YASHAR CM, AREND R, et al. NCCN Guidelines® Insights: Cervical Cancer, Version 1.2024[J]. J Natl Compr Canc Netw, 2023, 21( 12): 1224- 1233. DOI: 10.6004/jnccn.2023.0062.
    [15]
    MONK BJ, SILL MW, BURGER RA, et al. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: A gynecologic oncology group study[J]. J Clin Oncol, 2009, 27( 7): 1069- 1074. DOI: 10.1200/jco.2008.18.9043.
    [16]
    TEWARI KS, SILL MW, PENSON RT, et al. Bevacizumab for advanced cervical cancer: Final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial(Gynecologic Oncology Group 240)[J]. Lancet, 2017, 390( 10103): 1654- 1663. DOI: 10.1016/S0140-6736(17)31607-0.
    [17]
    ZHU J, SONG CY, ZHENG Z, et al. Anlotinib in Chinese patients with recurrent advanced cervical cancer: A prospective single-arm, open-label phase II trial[J]. Front Oncol, 2021, 11: 720343. DOI: 10.3389/fonc.2021.720343.
    [18]
    XU Q, WANG JJ, SUN Y, et al. Efficacy and safety of sintilimab plus anlotinib for PD-L1-positive recurrent or metastatic cervical cancer: A multicenter, single-arm, prospective phase II trial[J]. J Clin Oncol, 2022, 40( 16): 1795- 1805. DOI: 10.1200/jco.21.02091.
    [19]
    LAN CY, SHEN JX, WANG Y, et al. Camrelizumab plus apatinib in patients with advanced cervical cancer(CLAP): A multicenter, open-label, single-arm, phase II trial[J]. J Clin Oncol, 2020, 38( 34): 4095- 4106. DOI: 10.1200/jco.20.01920.
    [20]
    Society of Gynecological Oncology of Chinese Society of Clinical Oncology. Chinese expert consensus on the clinical applications of anti-angiogenic small molecule tyrosine kinase inhibitors in recurrent, metastatic or advanced gynecological tumors(2022 edition)[J]. Chin J Oncol Prev Treat, 2023, 15( 1): 1- 10. DOI: 10.3969/j.issn.1674-5671.2023.01.01.

    中国临床肿瘤协会(CSCO)妇科肿瘤专家委员会. 抗血管生成小分子酪氨酸激酶抑制剂在复发转移或晚期妇科肿瘤临床应用的中国专家共识(2022版)[J]. 中国癌症防治杂志, 2023, 15( 1): 1- 10. DOI: 10.3969/j.issn.1674-5671.2023.01.01.
    [21]
    VERGOTE I, VAN NIEUWENHUYSEN E, O’CEARBHAILL RE, et al. Tisotumab vedotin in combination with carboplatin, pembrolizumab, or bevacizumab in recurrent or metastatic cervical cancer: Results from the innovaTV 205/GOG-3024/ENGOT-cx8 study[J]. J Clin Oncol, 2023, 41( 36): 5536- 5549. DOI: 10.1200/jco.23.00720.
    [22]
    CHUNG HC, ROS W, DELORD JP, et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: Results from the phase II KEYNOTE-158 study[J]. J Clin Oncol, 2019, 37( 17): 1470- 1478. DOI: 10.1200/jco.18.01265.
    [23]
    NAUMANN RW, HOLLEBECQUE A, MEYER T, et al. Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: Results from the phase I/II CheckMate 358 trial[J]. J Clin Oncol, 2019, 37( 31): 2825- 2834. DOI: 10.1200/jco.19.00739.
    [24]
    TEWARI KS, MONK BJ, VERGOTE I, et al. Survival with cemiplimab in recurrent cervical cancer[J]. N Engl J Med, 2022, 386( 6): 544- 555. DOI: 10.1056/NEJMoa2112187.
    [25]
    COLOMBO N, DUBOT C, LORUSSO D, et al. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer[J]. N Engl J Med, 2021, 385( 20): 1856- 1867. DOI: 10.1056/NEJMoa2112435.
    [26]
    LOU HM, CAI HB, HUANG X, et al. Cadonilimab combined with chemotherapy with or without bevacizumab as first-line treatment in recurrent or metastatic cervical cancer(COMPASSION-13): A phase 2 study[J]. Clin Cancer Res, 2024, 30( 8): 1501- 1508. DOI: 10.1158/1078-0432.CCR-23-3162.
    [27]
    Society of Onco-Endocrinology of Chinese Anti-Cancer Association. Chinese expert consensus on immunotherapy for gynecological malignant tumors(2023 edition)[J]. China Oncol, 2023, 33( 10): 954- 968. DOI: 10.19401/j.cnki.1007-3639.2023.10.008.

    中国抗癌协会肿瘤内分泌专业委员会. 妇科恶性肿瘤免疫治疗中国专家共识(2023年版)[J]. 中国癌症杂志, 2023, 33( 10): 954- 968. DOI: 10.19401/j.cnki.1007-3639.2023.10.008.
    [28]
    NANCE ME, BIEDERMANN GB, BHAT AP, et al. Chemorefractory liver metastasis from cervical cancer successfully treated with a combination of yttrium-90 and immunotherapy[J]. Radiol Case Rep, 2020, 15( 8): 1359- 1365. DOI: 10.1016/j.radcr.2020.06.010.
    [29]
    SONG G. Carrelizumab in the treatment of liver metastasis of cervical cancer: A report of 2 cases[J]. Anhui Med J, 2021, 42( 3): 350- 351. DOI: 10.3969/j.issn.1000-0399.2021.03.030.

    宋耕. 卡瑞利珠单抗治疗宫颈癌肝转移2例报道[J]. 安徽医学, 2021, 42( 3): 350- 351. DOI: 10.3969/j.issn.1000-0399.2021.03.030.
    [30]
    BACALBASA N, BALESCU I, DIMA S, et al. Hepatic resection for liver metastases from cervical cancer is safe and may have survival benefit[J]. Anticancer Res, 2016, 36( 6): 3023- 3027.
    [31]
    KASEKI H, YASUI K, NIWA K, et al. Hepatic resection for metastatic squamous cell carcinoma from the uterine cervix[J]. Gynecol Oncol, 1992, 44( 3): 284- 287. DOI: 10.1016/0090-8258(92)90059-r.
    [32]
    TANGJITGAMOL S, LEVENBACK CF, BELLER U, et al. Role of surgical resection for lung, liver, and central nervous system metastases in patients with gynecological cancer: A literature review[J]. Int J Gynecol Cancer, 2004, 14( 3): 399- 422. DOI: 10.1111/j.1048-891x.2004.14326.x.
    [33]
    TOMITA K, MATSUI Y, UKA M, et al. Evidence on percutaneous radiofrequency and microwave ablation for liver metastases over the last decade[J]. Jpn J Radiol, 2022, 40( 10): 1035- 1045. DOI: 10.1007/s11604-022-01335-5.
    [34]
    HAN K, KIM JH, YANG SG, et al. A single-center retrospective analysis of periprocedural variables affecting local tumor progression after radiofrequency ablation of colorectal cancer liver metastases[J]. Radiology, 2021, 298( 1): 212- 218. DOI: 10.1148/radiol.2020200109.
    [35]
    WANG Q, LI B, SHI HF, et al. Radiofrequency ablation for metastatic lesions from gynecologic malignancies[J]. Chin J Interv Imaging Ther, 2015, 12( 7): 391- 394. DOI: 10.13929/j.1672-8475.2015.07.002.

    王勤, 李斌, 石海峰, 等. 射频消融治疗妇科恶性肿瘤转移性病变[J]. 中国介入影像与治疗学, 2015, 12( 7): 391- 394. DOI: 10.13929/j.1672-8475.2015.07.002.
    [36]
    ZHANG SY, ZHU GY, LI G, et al. Application of stereotactic body radiation therapy to cancer liver metastasis[J]. Cancer Lett, 2016, 379( 2): 225- 229. DOI: 10.1016/j.canlet.2015.10.029.
    [37]
    de POOTER JA, MÉNDEZ ROMERO A, WUNDERINK W, et al. Automated non-coplanar beam direction optimization improves IMRT in SBRT of liver metastasis[J]. Radiother Oncol, 2008, 88( 3): 376- 381. DOI: 10.1016/j.radonc.2008.06.001.
    [38]
    KAGARA N, NAKANO Y, WATANABE A, et al. Curative-intent stereotactic body radiation therapy for residual breast cancer liver metastasis after systemic chemotherapy[J]. Breast Cancer, 2014, 21( 6): 761- 764. DOI: 10.1007/s12282-011-0290-5.
    [39]
    REDDY AV, MILLS MN, RESHKO LB, et al. Stereotactic body radiation therapy in oligometastatic uterine cancer: Clinical outcomes and toxicity[J]. Cancer Investig, 2020, 38( 8-9): 522- 530. DOI: 10.1080/07357907.2020.1817483.
    [40]
    LI JB, ZHANG LA, ZHOU YL. Observation on the therapeutic effect of interventional therapy for advanced liver metastasis of cervical cancer[J]. J Front Med, 2016, 6( 14): 174- 175.

    李继兵, 张来安, 周杨林. 宫颈癌晚期肝脏转移瘤介入治疗疗效观察[J]. 医药前沿, 2016, 6( 14): 174- 175.
    [41]
    YIN ZM, TANG HR, LI L, et al. Impact of sites versus number of metastases on survival of patients with organ metastasis from newly diagnosed cervical cancer[J]. Cancer Manag Res, 2019, 11: 7759- 7766. DOI: 10.2147/cmar.s203037.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (845) PDF downloads(47) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return